Efficacy of epi-1 modified epirubicin and curcumin encapsulated liposomes targeting-EpCAM in the inhibition of epithelial ovarian cancer cells

Wang, Yujia; TANG, Ling; Lu, Xuhong; Liu, Ji-tao; Wang, Yuan‐Yuan; Geng, Hong-xia; Li, Xuetao; An, Quan

doi:10.1080/08982104.2022.2153138

Cited by 4 publications

(2 citation statements)

References 63 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, we determined the stability of HA-PDLPs and PEG-TK-HA-PDLPs over 21 days at 4 °C according to previous methods. 9 The release rate of PEG-TK-HA-PDLPs in vitro was determined using the dialysis method under sink conditions. 28 The EE% was calculated using the following formula: , where W loaded and W total represented the content of PTX or Dios in the liposomal suspension after and before passing through the Sephadex G-100 column, respectively.…”

Section: Methodsmentioning

confidence: 99%

“…To this end, new treatment options such as molecular targets are being investigated in OC clinical trials to combat OC. 8 , 9 Nevertheless, there are still some problems with these targeted drugs, such as insufficient circulation time of the drug in vivo and insignificant target specificity. Therefore, it is necessary to find more effective carrier systems that utilize nano-carriers to improve drug delivery efficiency and inhibit tumor cell proliferation and metastasis.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Construction of ROS-Responsive Hyaluronic Acid Modified Paclitaxel and Diosgenin Liposomes and Study on Synergistic Enhancement of Anti-Ovarian Cancer Efficacy

Tang,

Wang,

Wang

et al. 2024

IJN

Self Cite

View full text Add to dashboard Cite

Purpose Ovarian cancer is a fatal gynecologic malignancy with a high rate of abdominal metastasis. Chemotherapy still has a poor clinical prognosis for ovarian cancer patients, with cell proliferation and angiogenesis leading to invasion, migration, and recurrence. To overcome these obstacles, we constructed a novel HA-modified paclitaxel and diosgenin liposome (PEG-TK-HA-PDLPs) using two novel functional materials, DSPE-PEG 2000 -HA and DSPE-PEG 2000 -TK-PEG 5000 , to specifically deliver the drugs to the tumor site in order to reduce OC cell proliferation and anti-angiogenic generation, thereby inhibiting invasion and migration. Methods and Results PEG-TK-HA-PDLPs were prepared by film dispersion, with ideal physicochemical properties and exhibits active targeting for enhanced cellular uptake. The ZIP synergy score for PTX and Dios was calculated using the online SynergyFinder software to be 3.15, indicating synergy. In vitro results showed that PEG-TK-HA-PDLPs were highly cytotoxic to ID8 cells, induced ID8 cell apoptosis, and inhibited ID8 cell migration and invasion. In vivo studies showed that PEG-TK-HA-PDLPs could prolong the circulation time in the blood, accumulate significantly in the tumor site, and effectively fight against angiogenesis with significant anti-tumor effects. Conclusion The production of PEG-TK-HA-PDLPs is an effective strategy for the treatment of OC.

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Construction of ROS-Responsive Hyaluronic Acid Modified Paclitaxel and Diosgenin Liposomes and Study on Synergistic Enhancement of Anti-Ovarian Cancer Efficacy

Tang,

Wang,

Wang

et al. 2024

IJN

Self Cite

View full text Add to dashboard Cite

show abstract

Mannose-modified celastrol liposomes targeted activated macrophages for rheumatoid arthritis treatment in vitro and in vivo evaluation

Si,

Guo,

Zhang

et al. 2024

Journal of Drug Delivery Science and Technology

View full text Add to dashboard Cite

Comprehensive transcriptome and scRNA‐seq analyses uncover the expression and underlying mechanism of SYNJ2 in papillary thyroid carcinoma

Yang,

Huang,

Luo

et al. 2024

IET Systems Biology

View full text Add to dashboard Cite

Synaptojanin 2 (SYNJ2) has crucial role in various tumors, but its role in papillary thyroid carcinoma (PTC) remains unexplored. This study first detected SYNJ2 protein expression in PTC using immunohistochemistry method and further assessed SYNJ2 mRNA expression through mRNA chip and RNA sequencing data and its association with clinical characteristics. Additionally, KEGG, GSVA, and GSEA analyses were conducted to investigate potential biological functions, while single‐cell RNA sequencing data were used to explore SYNJ2's underlying mechanisms in PTC. Meanwhile, immune infiltration status in different SYNJ2 expression groups were analyzed. Besides, we investigated the immune checkpoint gene expression and implemented drug sensitivity analysis. Results indicated that SYNJ2 is highly expressed in PTC (SMD = 0.66 [95% CI: 0.17–1.15]) and could distinguish between PTC and non‐PTC tissues (AUC = 0.74 [0.70–0.78]). Furthermore, the study identified 134 intersecting genes of DEGs and CEGs, mainly enriched in the angiogenesis and epithelial‐mesenchymal transition (EMT) pathways. Subsequent analysis showed the above pathways were activated in PTC epithelial cells. PTC patients with high SYNJ2 expression showed higher sensitivity to the six common drugs. Summarily, SYNJ2 may promote PTC progression through angiogenesis and EMT pathways. High SYNJ2 expression is associated with better response to immunotherapy and chemotherapy.

show abstract

Efficacy of epi-1 modified epirubicin and curcumin encapsulated liposomes targeting-EpCAM in the inhibition of epithelial ovarian cancer cells

Cited by 4 publications

References 63 publications

Construction of ROS-Responsive Hyaluronic Acid Modified Paclitaxel and Diosgenin Liposomes and Study on Synergistic Enhancement of Anti-Ovarian Cancer Efficacy

Construction of ROS-Responsive Hyaluronic Acid Modified Paclitaxel and Diosgenin Liposomes and Study on Synergistic Enhancement of Anti-Ovarian Cancer Efficacy

Mannose-modified celastrol liposomes targeted activated macrophages for rheumatoid arthritis treatment in vitro and in vivo evaluation

Comprehensive transcriptome and scRNA‐seq analyses uncover the expression and underlying mechanism of SYNJ2 in papillary thyroid carcinoma

Contact Info

Product

Resources

About